One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Efficacy, Toxicity, and Cosmesis of Partial Breast Irradiation: Honing in on Dose and Patient Selection
doi : 10.1200/JCO-24-01625
2025, Volume 43 (5)
Closing the Gap: Evaluating Medicare's Low-Income Subsidy Support for Optimal Cancer Care
doi : 10.1200/JCO-24-02197
Further Optimizing Care of Patients With Operable Hormone Receptor–Sensitive Breast Cancer
doi : 10.1200/JCO.24.01080
Finding the Right Partner: Triplet Therapy for First-Line Advanced Biliary Tract Cancers
doi : 10.1200/JCO-24-02089
Phase I Trial of MCARH109, a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis
doi : 10.1200/JCO-24-01785
OPAR: A Randomized Trial of Partial Breast Irradiation in Five Fractions Once Daily for Early Breast Cancer
doi : 10.1200/JCO.24.00600
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)
doi : 10.1200/JCO.24.00529
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
doi : 10.1200/JCO-24-01383
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial
doi : 10.1200/JCO.24.00337
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
doi : 10.1200/JCO.24.00321
JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL
doi : 10.1200/JCO.24.00811
Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer
doi : 10.1200/JCO.24.00646
Liver Transplantation for Hepatocellular Carcinoma: An Expanding Cornerstone of Care in the Era of Immunotherapy
doi : 10.1200/JCO.24.00857
Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline
doi : 10.1200/JCO-24-02120
Peak Corticosteroid Dose for Immune-Related Adverse Events and Survival: Not the Whole Story
doi : 10.1200/JCO-24-01878
Reply to: Peak Corticosteroid Dose for Immune-Related Adverse Events and Survival: Not the Whole Story
doi : 10.1200/JCO-24-02234
Optimizing DeepHRD Interpretability for Enhanced Clinical Decision Making
doi : 10.1200/JCO-24-01870
Reply to: Optimizing DeepHRD Interpretability for Enhanced Clinical Decision Making
doi : 10.1200/JCO-24-02279
Erratum: Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors
doi : 10.1200/JCO-24-02691
Erratum: Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update
doi : 10.1200/JCO-24-02719
